Tigris Pharmaceuticals

company

About

Tigris Pharmaceuticals is a biopharmaceutical company developing therapeutic technologies for cancer and other unmet medical needs.

  • 1 - 10

Details

Last Funding Type
Series B
Last Funding Money Raised
$16M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2005
Number Of Employee
1 - 10
Operating Status
Active

Tigris Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutic technologies for oncology and other areas of unmet medical need. Its products include Aminoflavone that is for the treatment of renal cell, breast, and lung cancer; GGTI-2418, a synthetic peptidomimetic inhibitor of geranylgeranyltransferase, which is for the treatment of lung, breast, pancreatic, and ovarian cancer; GFB-204, a calixarene derivative that is a potent and selective inhibitor of VEGFR and PDGFR tyrosine phosphorylation, which is for the treatment of prostate, pancreas, lung, breast, and renal cell. The company was founded in 2005 and is based in Bonita Springs, Florida.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$22.50M
Tigris Pharmaceuticals has raised a total of $22.50M in funding over 2 rounds. Their latest funding was raised on Sep 28, 2010 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 28, 2010 Series C $6.50M 1 Detail
Jan 17, 2007 Series B $16M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Tigris Pharmaceuticals is funded by 1 investors. Riverbank Capital Securities are the most recent investors.
Investor Name Lead Investor Funding Round
Riverbank Capital Securities Series C